title: [Protective effects of Lovastatin on early diabetic renal tissue and the possible mechanism].
abstract: OBJECTIVE
  To investigate the protective effects of Lovastatin on renal function in experimental diabetic nephropathy in rats. and the function of cAMP-responsive element binding protein (CREB1) in this duration.
  
  
  METHODS
  Diabetes was induced in male Wistar rats by intrapetitoneal injection of STZ (65 mg/kg). Three groups were divided as: Sham group, diabetic control group and Lovastatin treatment group. Lovastatin (20 mg/kg) was administered daily by gavage from the next day of the induction diabetes for 4 weeks. Upro, ucr in urine and Glu, Scr, BUN in serum were determined. Immunohistochemistry and computer image-pattern analysis system were used to analyze expression of PCNA and p-CREB1. Western blot were performed to valuate the expression of p-CREB1 with their specific corresponding antibodies. CREB1 mRNA was measured by RT-PCR.
  
  
  RESULTS
  After Lovastatin treatment, renal function were ameliorative in diabetic rats. Decrements were also found in the expression of and PCNA, p-CREB1 and its mRNA in the treatment group compared with the diabetic group.
  
  
  CONCLUSIONS
  Inhibition of glomerular cAMP-responsive element binding protein 1 may be responsible for the Lovastatin protective function that allevate the renal proliferation and hypertrophy in diabetic rats.
authors.affiliation: Department of Pathology, Hebei Medical University, Shijiazhuang 050017, China. wanglh68@163.com
authors.forename: Li-Hui
authors.initials: LH
authors.lastname: Wang
authors.forename: Hui-Jun
authors.initials: HJ
authors.lastname: Duan
authors.forename: Yong-Hong
authors.initials: YH
authors.lastname: Shi
authors.forename: Qing-Juan
authors.initials: QJ
authors.lastname: Liu
mesh_terms: D051698:Activating Transcription Factor 2 / Q000378:metabolism*; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D007677:Kidney Function Tests; D008148:Lovastatin / Q000627:therapeutic use*; D008297:Male; D020011:Protective Agents / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar
chemical_list: D051698:Activating Transcription Factor 2; C497107:Atf2 protein, rat; D020011:Protective Agents; D008148:Lovastatin